Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 14/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6277594 | 0.85 | ALDH1A1 (0.64) | ALDH1A1CYP1A2MEN1KMT2AHSD17B10 | |
| SCHEMBL6274384 | 0.84 | ALDH1A1 (0.64) | ALDH1A1MEN1KMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL1702494 | 0.84 | ALDH1A1 (0.64) | ALDH1A1MEN1KMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL1702862 | 0.83 | ALDH1A1 (0.56) | ALDH1A1CYP1A2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13547708 | 0.83 | ALDH1A1 (0.62) | ALDH1A1MEN1KMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL6278534 | 0.83 | ALDH1A1 (0.65) | ALDH1A1MEN1KMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL1703004 | 0.82 | ALDH1A1 (0.52) | ALDH1A1CYP1A2MEN1KMT2AHSD17B10 | |
| SCHEMBL6279104 | 0.82 | ALDH1A1 (0.70) | ALDH1A1CYP1A2MEN1KMT2AHSD17B10 | |
| SCHEMBL1755253 | 0.81 | TP53 (0.65) | ALDH1A1CYP1A2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6274361 | 0.81 | ALDH1A1 (0.70) | ALDH1A1MEN1KMT2AHSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017479-B2 | Process to make non nucleosidal reverse transcriptase inhibitors (NNRTI) for the treatment of HIV | ROSOCHA GREGORY (CA) | 2018-07-10 | — | — | US | disclosed |
| US-10017479-B2 | Process to make non nucleosidal reverse transcriptase inhibitors (NNRTI) for the treatment of HIV | ROSOCHA GREGORY (CA) | 2018-07-10 | — | — | US | disclosed |
| US-10017479-B2 | Process to make non nucleosidal reverse transcriptase inhibitors (NNRTI) for the treatment of HIV | ROSOCHA GREGORY (CA) | 2018-07-10 | — | — | US | disclosed |
| US-20160130238-A1 | New Process to make non nucleosidal reverse transcriptase inhibitors (NNRTI) for the treatment of HIV | ROSOCHA GREGORY (CA) | 2016-05-12 | — | — | US | disclosed |
| US-20160130238-A1 | New Process to make non nucleosidal reverse transcriptase inhibitors (NNRTI) for the treatment of HIV | ROSOCHA GREGORY (CA) | 2016-05-12 | — | — | US | disclosed |
| WO-2015015240-A1 | NEW PROCESS TO MAKE NON-NUCLEOSIDAL REVERSE TRANSCRIPTASE INHIBITORS (NNRTI) FOR THE TREATMENT OF HIV | ROSOCHA GREGORY (CA) | 2015-02-05 | — | — | WO | disclosed |
| WO-2015015240-A1 | NEW PROCESS TO MAKE NON-NUCLEOSIDAL REVERSE TRANSCRIPTASE INHIBITORS (NNRTI) FOR THE TREATMENT OF HIV | ROSOCHA GREGORY (CA) | 2015-02-05 | — | — | WO | disclosed |
| EP-1569919-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2012-04-18 | — | — | EP | disclosed |
| EP-1569919-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2012-04-18 | — | — | EP | disclosed |
| US-7642277-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-05 | — | — | US | disclosed |
| US-7642277-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-05 | — | — | US | disclosed |
| US-7642277-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-05 | — | — | US | disclosed |
| CN-1720043-A | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2006-01-11 | — | — | CN | disclosed |
| WO-2005115147-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| EP-1569919-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2005-09-07 | — | — | EP | disclosed |
| US-20050054639-A1 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-03-10 | — | — | US | disclosed |
| US-20050054639-A1 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-03-10 | — | — | US | disclosed |
| WO-2004050643-A3 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004050643-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017479-B2 | Process to make non nucleosidal reverse transcriptase inhibitors (NNRTI) for the treatment of HIV | DNTT, NNMT, PNP | ALDH1A1 1878/4885CYP1A2 945/4885MEN1 4680/4885 |
| US-20050054639-A1 | Non-nucleoside reverse transcriptase inhibitors | NAT1, SUB1, RTF2 | ALDH1A1 1533/4885CYP1A2 289/4885MEN1 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.